Thrombosis, bleeding, and evolution risk factors: multivariate analyses
| Risk factors for thrombosis . | Whole cohort . | ET . | PV . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Multivariate analysis . | OR . | 95% CI . | P . | OR . | 95% CI . | P . | OR . | 95% CI . | P . |
| JAK2 vs other mutations | 3.49 | 1.26-9.66 | .016 | 3.40 | 1.15-10.09 | .027 | NA | ||
| Hyperviscosity vs no | 2.37 | 1.04-5.41 | .040 | 2.98 | 1.12-7.90 | .028 | NA | ||
| Constitutional symptoms vs no | 2.11 | 0.55-8.17 | .279 | 3.43 | 0.60-19.79 | .167 | NA | ||
| Cardiovascular RF vs no | 1.60 | 0.50-5.09 | .430 | NA | 3.35 | 0.25-45.37 | .363 | ||
| Thrombosis history vs no | 0.93 | 0.26-3.40 | .916 | NA | NA | ||||
| Leukocytes > 11 g/L vs no | NA | NA | 6.30 | 0.67-59.07 | .107 | ||||
| Risk factors for thrombosis . | Whole cohort . | ET . | PV . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Multivariate analysis . | OR . | 95% CI . | P . | OR . | 95% CI . | P . | OR . | 95% CI . | P . |
| JAK2 vs other mutations | 3.49 | 1.26-9.66 | .016 | 3.40 | 1.15-10.09 | .027 | NA | ||
| Hyperviscosity vs no | 2.37 | 1.04-5.41 | .040 | 2.98 | 1.12-7.90 | .028 | NA | ||
| Constitutional symptoms vs no | 2.11 | 0.55-8.17 | .279 | 3.43 | 0.60-19.79 | .167 | NA | ||
| Cardiovascular RF vs no | 1.60 | 0.50-5.09 | .430 | NA | 3.35 | 0.25-45.37 | .363 | ||
| Thrombosis history vs no | 0.93 | 0.26-3.40 | .916 | NA | NA | ||||
| Leukocytes > 11 g/L vs no | NA | NA | 6.30 | 0.67-59.07 | .107 | ||||
| Risk factors for bleeding . | Whole cohort . | ET . | PV . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Multivariate analysis . | OR . | 95% CI . | P . | OR . | 95% CI . | P . | OR . | 95%CI . | P . |
| Hyperviscosity vs no | 3.06 | 1.24-7.56 | .015 | 7.40 | 2.10-26.10 | .002 | NA | ||
| Palpable splenomegaly vs no | 2.82 | 1.33-7.04 | .026 | NA | NA | ||||
| Cardiovascular RF vs no | 1.74 | 0.54-5.62 | .355 | NA | NA | ||||
| Bleeding history vs no | 10.93 | 3.23-37.07 | .000 | 48.79 | 9.30-256.05 | .000 | NA | ||
| Platelets > 1500 g/L vs no | 2.92 | 1.09-7.87 | .034 | 4.97 | 1.37-18.05 | .002 | NA | ||
| Age < 20 y vs no | NA | 0.09 | 0.02-0.43 | .002 | NA | ||||
| Risk factors for bleeding . | Whole cohort . | ET . | PV . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Multivariate analysis . | OR . | 95% CI . | P . | OR . | 95% CI . | P . | OR . | 95%CI . | P . |
| Hyperviscosity vs no | 3.06 | 1.24-7.56 | .015 | 7.40 | 2.10-26.10 | .002 | NA | ||
| Palpable splenomegaly vs no | 2.82 | 1.33-7.04 | .026 | NA | NA | ||||
| Cardiovascular RF vs no | 1.74 | 0.54-5.62 | .355 | NA | NA | ||||
| Bleeding history vs no | 10.93 | 3.23-37.07 | .000 | 48.79 | 9.30-256.05 | .000 | NA | ||
| Platelets > 1500 g/L vs no | 2.92 | 1.09-7.87 | .034 | 4.97 | 1.37-18.05 | .002 | NA | ||
| Age < 20 y vs no | NA | 0.09 | 0.02-0.43 | .002 | NA | ||||
| Risk factors for evolution . | Whole cohort . | ET . | PV . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Multivariate analysis . | OR . | 95% CI . | P . | OR . | 95%CI . | P . | OR . | 95% CI . | P . |
| Palpable splenomegaly vs no | NA | 8.42 | 3.58-19.77 | .000 | NA | ||||
| Cardiovascular RF vs no | NA | 3.98 | 1.48-10.68 | .006 | NA | ||||
| Thrombosis history vs no | NA | NA | 5.88 | 1.15-30.09 | .033 | ||||
| Age < 20 y vs no | NA | NA | 9.63 | 1.04-88.79 | .046 | ||||
| Risk factors for evolution . | Whole cohort . | ET . | PV . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Multivariate analysis . | OR . | 95% CI . | P . | OR . | 95%CI . | P . | OR . | 95% CI . | P . |
| Palpable splenomegaly vs no | NA | 8.42 | 3.58-19.77 | .000 | NA | ||||
| Cardiovascular RF vs no | NA | 3.98 | 1.48-10.68 | .006 | NA | ||||
| Thrombosis history vs no | NA | NA | 5.88 | 1.15-30.09 | .033 | ||||
| Age < 20 y vs no | NA | NA | 9.63 | 1.04-88.79 | .046 | ||||
RF, risk factors; NA, not applicable.